Skip to content
Abierto
Menu

Award notice

PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers, Preclinical Services for cGMP Biopharmaceutical Product Development and Manufacturing, and Toxicology and Pharmacology Testing

75N91024D00008

National Institutes of Health, NIH NCI. Research and Development in Biotechnology (except Nanobiotechnology).

View on SAM.govMarkdown

Awarded

Curia Bio Inc.

$149,995,000.00 on the award notice, September 13, 2024, contract 75N91024D00008

Description

As published on SAM.gov.

This is an IDIQ award (with potential fixed-price and cost plus fixed fee task orders) associated with the CGMP Pool under the PREVENT Preclinical Drug Development Program awarded competitively.

The contract, on USAspending

Federal procurement data the awarding office reported to FPDS, matched to this solicitation by its number.

Recipient
Curia Bio Inc.
UEI
PW5LPREDN9N5
CAGE
9TMX2
Vendor location
Belmont, CA
Contract
75N91024D00008
Obligated
$0.00, potential $149,995,000
Actions
2 between September 13, 2024 and June 25, 2026
Competition
Full and Open Competition, 2 offers received
Set-aside reported
No Set Aside Used.
Described as
Prevent Cancer Preclinical Drug Development Program: CGMP
Match
award number 75N91024D00008 equals the contract number; same awarding office 75N910 (high confidence)
Record
USAspending award page

Publications

Every notice SAM.gov issued under this solicitation number, oldest first. Each is a separate record on SAM.

  1. September 16, 2024

    Award notice, originally solicitation

    Awarded to CURIA BIO Inc. Albany for $149,995,000. SAM.gov, notice 8f62eacf01814c149d890de2e0816392

Points of contact

Also open from this buyer